Patents by Inventor Kato L. Perlman
Kato L. Perlman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5486636Abstract: New compounds of the formula ##STR1## where Y' represents hydroxy, protected-hydroxy, O-tosyl, O-mesyl, bromine, chlorine, or iodine and X.sup.1 and X.sup.2 may independently represent hydrogen or a hydroxy-protecting group are useful as intermediates for the production of 19-nor vitamin D derivatives, particularly 1.alpha.,25-dihydroxyvitamin D.sub.3, from (-)quinic acid.Type: GrantFiled: October 26, 1994Date of Patent: January 23, 1996Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman, Rolf E. Swenson
-
Patent number: 5414098Abstract: The invention provides new 24, 26, and/or 27 homologated vitamin D.sub.2 compounds, such as 26,27-dihomo-1.alpha.-hydroxyvitamin D.sub.2, 26,27-dihomo-1.alpha.-hydroxy-24-epi-vitamin D.sub.2, 26,27-dihomo-1.alpha.,25-dihydroxy-24-epi-vitamin D.sub.2 and certain hydroxy-protected derivatives thereof. The new epi compounds in particular exhibit a distinctive activity pattern comprising high potency in stimulating intestinal calcium transport and little or no activity in inducing bone calcium mobilization or the differentiation of undifferentiated cells in culture, thereby evincing utility in the treatment of diseases characterized by loss of bone mass. In contrast, the natural form exhibits no activity in either mobilizing calcium from bone or stimulating intestinal calcium transport. A process for preparing such compounds is also disclosed.Type: GrantFiled: December 3, 1992Date of Patent: May 9, 1995Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman
-
Patent number: 5397776Abstract: A birth control method for a female mammal which comprises administering to the mammal an amount of a vitamin D compound sufficient to block binding of progesterone to the progesterone receptor in said mammal.Type: GrantFiled: August 20, 1993Date of Patent: March 14, 1995Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Kato L. Perlman, Hisham M. Darwish
-
Patent number: 5391755Abstract: A convergent synthesis of 19-nor-vitamin D compounds, specifically 19-nor-1.alpha.,25-dihydroxyvitamin D.sub.3, is disclosed. The synthesis can also readily be utilized for preparing other 1.alpha.-hydroxylated 19-nor-vitamin D compounds. The key step in the synthesis is a suitable application of Lythgoe's procedure i.e. a Horner-Wittig reaction of the lithium anion of a phosphine oxide with a Windaus Grundmann ketone to give, after any necessary deprotection, the desired 19-nor-vitamin D compound.Type: GrantFiled: January 13, 1994Date of Patent: February 21, 1995Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman, Rolf E. Swenson
-
Patent number: 5354744Abstract: This invention provides novel vitamin D-related compounds characterized by extended unsaturated side chain structures. Such compounds exhibit increased activity in arresting the proliferation and promoting the differentiation of malignant cells with only minimal calcemic activity and thus represents new therapeutic agents applicable and uniquely useful in differentiation therapy of malignant diseases. The activity characteristics of these compounds provide the basis of a method for the treatment of neoplastic diseases, specifically leukemoid diseases.Type: GrantFiled: December 31, 1992Date of Patent: October 11, 1994Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman
-
Patent number: 5342975Abstract: This invention provides a novel class of vitamin D-related compounds, namely the 1.alpha.-hydroxy-19-nor-vitamin D analogs, as well as a general method for their chemical synthesis. The compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells, including malignant cells, and in inducing their differentiation, and thus represent novel therapeutic agents for the treatment of malignant and other diseases characterized by the proliferative growth of undifferentiated cells. Formulations for therapeutic use and treatment methods are also provided.Type: GrantFiled: September 17, 1993Date of Patent: August 30, 1994Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman, Rafal R. Sicinski, Jean M. Prahl
-
Patent number: 5281731Abstract: A convergent synthesis of 19-nor-vitamin D compounds, specifically 19-nor-1.alpha.,25-dihydroxyvitamin D.sub.3, is disclosed. The synthesis can also readily be utilized for preparing other 1.alpha.-hydroxylated 19-nor-vitamin D compounds. The key step in the synthesis is a suitable application of Lythgoe's procedure i.e. a Horner-Wittig reaction of the lithium anion of a phosphine oxide with a Windaus Grundmann ketone to give, after any necessary deprotection, the desired 19-nor-vitamin D compound.Type: GrantFiled: November 20, 1992Date of Patent: January 25, 1994Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman, Rolf E. Swenson
-
Patent number: 5260290Abstract: The invention provides new 24, 26, and/or 27 homologated vitamin D.sub.2 compounds, such as 26,27-dihomo-1.alpha.-hydroxyvitamin D.sub.2, 26,27-dihomo-1.alpha.-hydroxy-24-epi-vitamin D.sub.2, 26,27-dihomo-1.alpha.,25-dihydroxy-24-epi-vitamin D.sub.2 and certain hydroxy-protected derivatives thereof. The new epi compounds in particular exhibit a distinctive activity pattern comprising high potency in stimulating intestinal calcium transport and little or no activity in inducing bone calcium mobilization or the differentiation of undifferentiated cells in culture, thereby evincing utility in the treatment of diseases characterized by loss of bone mass. In contrast, the natural form exhibits no activity in either mobilizing calcium from bone or stimulating intestinal calcium transport. A process for preparing such compounds is also disclosed.Type: GrantFiled: February 13, 1991Date of Patent: November 9, 1993Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman
-
Patent number: 5250523Abstract: This invention provides novel vitamin D-related compounds characterized by extended unsaturated side chain structures. Such compounds exhibit increased activity in arresting the proliferation and promoting the differentiation of malignant cells with only minimal calcemic activity and thus represents new therapeutic agents applicable and uniquely useful in differentiation therapy of malignant diseases. The activity characteristics of these compounds provide the basis of a method for the treatment of neoplastic diseases, specifically leukemoid diseases.Type: GrantFiled: February 14, 1990Date of Patent: October 5, 1993Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman
-
Patent number: 5246925Abstract: This invention provides a novel class of vitamin D-related compounds, namely the 1.alpha.-hydroxy-19-nor-vitamin D analogs, as well as a general method for their chemical synthesis. The compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells, including malignant cells, and in inducing their differentiation, and thus represent novel therapeutic agents for the treatment of malignant and other diseases characterized by the proliferative growth of undifferentiated cells. Formulations for therapeutic use and treatment methods are also provided.Type: GrantFiled: October 13, 1992Date of Patent: September 21, 1993Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman, Rafal R. Sicinski, Jean M. Prahl
-
Patent number: 5237110Abstract: This invention provides a novel class of vitamin D-related compounds, namely the 1.alpha.-hydroxy-19-nor-vitamin D analogs, as well as a general method for their chemical synthesis. The compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells, including malignant cells, and in inducing their differentiation, and thus represent novel therapeutic agents for the treatment of malignant and other diseases characterized by the proliferative growth of undifferentiated cells. Formulations for therapeutic use and treatment methods are also provided.Type: GrantFiled: February 16, 1990Date of Patent: August 17, 1993Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman, Rafal R. Sicinski, Jean M. Prahl
-
Patent number: 5089641Abstract: This invention provides a new method of making secosterol compounds, and in particular to the preparation of 1.alpha.-hydroxy-homopregnacalciferol which is a secosterol compound that is effective in inducing the differentiation of malignant cells and is therefore useful for the treatment of malignancies such as leukemia.Type: GrantFiled: March 11, 1991Date of Patent: February 18, 1992Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman
-
Method for preparing intermediates for the synthesis of steroid side chains in optically active form
Patent number: 5089647Abstract: This invention provides a novel method for the preparation of optically active arylalykylsulfone derivatives, having a chiral center in the alkyl moiety in either the (R)- or the (S)-configuration. These optically active sulfones find use in the stereospecific synthesis of steroid or vitamin D compounds having chiral center at either carbon 24 or carbon 25 of the side chain. The method comprises the steps of reacting an optically active sulfinate ester having a chiral center at sulfur with a racemic alkyl Grignard reagent to obtain a mixture of diastereomeric sulfoxides, separating the mixture of diastereomeric sulfoxides, and oxidizing separately each of the diastereomers to obtain the desired optically active sulfone.Type: GrantFiled: April 11, 1990Date of Patent: February 18, 1992Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman -
Patent number: 5086191Abstract: New intermediate compounds that can be used effectively for the synthesis of a broad range of 1.alpha.-hydroxy-19-nor-vitamin D compounds. These novel intermediates are characterized by a group selected from hydroxy methyl (--CH.sub.2 OH), carboxaldehyde (--CHO), and carboxy ester (--COOAlkyl) at the carbon 22 position of the side chain of a 19-nor-vitamin D nucleus. Intermediates of this type are useful for the introduction of side chain units and thus represent important synthons for the preparation of many different 19-nor-vitamin D compounds.Type: GrantFiled: May 28, 1991Date of Patent: February 4, 1992Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman
-
Patent number: 5061699Abstract: This invention provides novel side chain homologs of 1.alpha.,25-dihydroxyvitamin D.sub.3 which exhibit enhanced and highly selective activity in inducing differentiation of malignant cells. It also provides a general method of synthesis applicable to the preparation of a variety of vitamin D side chain analogs, and a method of treatment of neoplastic diseases which takes advantage of the selective differentiation activity of the new vitamin D homologs.Type: GrantFiled: October 10, 1989Date of Patent: October 29, 1991Inventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman, Andrzej Kutner
-
Patent number: 4973584Abstract: The invention provides a new vitamin D.sub.2 compound, 1.alpha.-hydroxy-24-epi-vitamin D.sub.2 and certain hydroxy-protected derivatives thereof. The new compound exhibits a distinctive activity pattern comprising high potency in stimulating intestinal calcium transport and little or no activity in inducing bone calcium mobilization or the differentiation of undifferentiated cells in culture, thereby evincing utility in the treatment of diseases characterized by loss of bone mass.Type: GrantFiled: March 9, 1989Date of Patent: November 27, 1990Inventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman
-
Patent number: 4927815Abstract: This invention provides novel side chain homologs of 1.alpha.,25-dihydroxyvitamin D.sub.3 which exhibit enhanced and highly selective activity in inducing differentiation of malignant cells. It also provides a general method of synthesis applicable to the preparation of a variety of vitamin D side chain analogs, and a method of treatment of neoplastic diseases which takes advantage of the selective differentiation activity of the new vitamin D homologs.Type: GrantFiled: April 29, 1988Date of Patent: May 22, 1990Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman, Andrzej Kutner
-
Patent number: 4851401Abstract: This invention provides novel 1.alpha.-hydroxyvitamin D compounds, methods for their preparation, and pharmaceutical compositions of these compounds. The new compounds, which are characterized structurally by having a cyclopentane ring as part of their side chains, exhibit highly pronounced biological activity, both in terms of their effect on calcium metabolism and their effect on differentiating malignant cells to normal cells. By virtue of their biological properties, the new vitamin D analogs are effective as calcium-regulating, or differentiation-inducing agents, and thus find application as therapeutic agents in the treatment or prophylaxis of bone-related as well as neoplastic diseases.Type: GrantFiled: July 14, 1988Date of Patent: July 25, 1989Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Kato L. Perlman, Andrzej Kutner
-
Patent number: 4847012Abstract: The invention relates to a method for preparing vitamin D-related compounds and to certain intermediate compounds in such process. The intermediate compounds are characterized by an aldehyde or ester in the C-22 position in the side chain. The presence of such groups permit facile side chain additions for the preparation of vitamin D derivatives.Type: GrantFiled: April 29, 1988Date of Patent: July 11, 1989Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Heinrich K. Schnoes, Andrzej Kutner, Kato L. Perlman, Rafal R. Sicinski, Mary E. Phelps